Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BLFS 
BioLife Solutions Inc (BLFS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: BLFS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.22
1 Year Target Price $31.22
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.86% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 994.02M USD | Price to earnings Ratio - | 1Y Target Price 31.22 |
Price to earnings Ratio - | 1Y Target Price 31.22 | ||
Volume (30-day avg) 9 | Beta 1.82 | 52 Weeks Range 19.10 - 29.55 | Updated Date 07/16/2025 |
52 Weeks Range 19.10 - 29.55 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -11.86% | Operating Margin (TTM) -5.09% |
Management Effectiveness
Return on Assets (TTM) -0.79% | Return on Equity (TTM) -2.52% |
Valuation
Trailing PE - | Forward PE 250 | Enterprise Value 991699412 | Price to Sales(TTM) 11.33 |
Enterprise Value 991699412 | Price to Sales(TTM) 11.33 | ||
Enterprise Value to Revenue 11.3 | Enterprise Value to EBITDA 365.27 | Shares Outstanding 47835200 | Shares Floating 37920046 |
Shares Outstanding 47835200 | Shares Floating 37920046 | ||
Percent Insiders 2.84 | Percent Institutions 100.53 |
Upturn AI SWOT
BioLife Solutions Inc
Company Overview
History and Background
BioLife Solutions Inc. was founded in 1998. It initially focused on developing biopreservation media for cells and tissues used in research. Over time, it expanded its product portfolio through acquisitions and internal development, becoming a leading provider of biopreservation tools and services for the cell and gene therapy market.
Core Business Areas
- Biopreservation Media: BioLife develops, manufactures, and markets biopreservation media such as CryoStor and HypoThermosol, used to protect cells and tissues during freezing and thawing. This segment contributes the most to the company's revenue.
- Bioproduction: This segment includes cell thawing and washing systems (ThawSTAR), automated liquid nitrogen freezers (CryoPod), and related consumables and services, offering solutions for bioprocessing and cryopreservation workflows.
- Cell Processing: This segment includes the acquisition of Sexton Biotechnologies, providing specialized tools for cell and gene therapy manufacturing, including cell culture media, reagents, and processing platforms.
Leadership and Structure
BioLife Solutions is led by its Chief Executive Officer (CEO) and has a structured executive team overseeing various functional areas. The company operates through several divisions focusing on specific product lines or services. The board of directors provides oversight and guidance on strategy and governance.
Top Products and Market Share
Key Offerings
- CryoStor: CryoStor is a family of cryopreservation media used to protect cells during freezing and thawing. The company estimates to have over 60% of the cell and gene therapy market and claim to have supported over 600 clinical applications. Competitors include STEMCELL Technologies, Cook Regentec, and Irvine Scientific. Revenues are unavailable, however the biopreservation media segment is the highest performing segement for BioLife Solutions.
- HypoThermosol: HypoThermosol is a hypothermic preservation media used to protect cells at refrigerated temperatures. Again the company estimates to have over 60% of the cell and gene therapy market. Competitors include STEMCELL Technologies, Cook Regentec, and Irvine Scientific. Revenues are unavailable, however the biopreservation media segment is the highest performing segement for BioLife Solutions.
- ThawSTAR: ThawSTAR is an automated thawing system for cryopreserved cells, intended to standardize and streamline the thawing process. The company estimates to have over 60% of the cell and gene therapy market. Competitors include GE Healthcare, and Miltenyi Biotec. Revenues are unavailable.
Market Dynamics
Industry Overview
The biopreservation market is driven by the growth of cell and gene therapy, regenerative medicine, and drug discovery. Demand for efficient and reliable biopreservation tools and services continues to increase, fuelled by ongoing research and development in these fields.
Positioning
BioLife Solutions is a leading provider of biopreservation tools and services, specifically tailored to the needs of cell and gene therapy companies. Their competitive advantages include a broad product portfolio, strong brand reputation, and extensive industry expertise.
Total Addressable Market (TAM)
The TAM for biopreservation is estimated to be in the billions of dollars annually, driven by the growth of the cell and gene therapy market. BioLife Solutions is well-positioned to capture a significant share of this growing market through its innovative products and services.
Upturn SWOT Analysis
Strengths
- Leading market position in biopreservation for cell and gene therapy
- Broad product portfolio covering multiple stages of the biopreservation workflow
- Strong brand reputation and customer loyalty
- Strategic acquisitions to expand product offerings and market reach
Weaknesses
- Dependence on the growth of the cell and gene therapy market
- Potential impact of new regulations on the biopreservation industry
- Intense competition
Opportunities
- Expanding product offerings to address new applications in biopreservation
- Entering new geographic markets with high growth potential
- Partnerships and collaborations with leading cell and gene therapy companies
- Expanding service offerings
Threats
- Emergence of new and disruptive biopreservation technologies
- Increased competition from established and emerging players
- Economic downturn impacting the cell and gene therapy market
- Supply chain disruptions and raw material shortages
Competitors and Market Share
Key Competitors
- STEM
- GE
- MTNDY
Competitive Landscape
BioLife Solutions benefits from a strong reputation. However, competitors are introducing competing solutions that are constantly improving upon exisiting standards. The company maintains a strong lead with continuous investment.
Major Acquisitions
Sexton Biotechnologies
- Year: 2021
- Acquisition Price (USD millions): 24
- Strategic Rationale: Expanded portfolio of cell and gene therapy tools, strengthens manufacturing, and access to key technologies.
Growth Trajectory and Initiatives
Historical Growth: BioLife Solutions has historically grown through a combination of organic revenue growth and strategic acquisitions.
Future Projections: Future growth projections are based on the continued expansion of the cell and gene therapy market, as well as the company's ability to introduce new products and expand its market share. Analyst estimates typically project continued revenue growth in the coming years.
Recent Initiatives: Recent initiatives include new product launches, strategic acquisitions of Sexton Biotechnologies, and partnerships with leading cell and gene therapy companies.
Summary
BioLife Solutions is a key player in the biopreservation market, especially in the cell and gene therapy space. The company's strength lies in its diverse product range and strategic acquisitions. However, it must be aware of increased competition and reliance on the expanding cell and gene therapy market to continue its growth trajectory. The company has been investing in research and development to further it's lead and is well positioned to remain competitive.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Analyst reports
- Press releases
- Third-party market research reports
- SEC Filings
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market conditions and company performance can change, and future results may differ from current expectations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLife Solutions Inc
Exchange NASDAQ | Headquaters Bothell, WA, United States | ||
IPO Launch date 1989-11-22 | CEO & Chairman Mr. Roderick de Greef | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 159 | Website https://www.biolifesolutions.com |
Full time employees 159 | Website https://www.biolifesolutions.com | ||
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.